These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 31562206)

  • 21. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogenic in situ hybridisation (CISH) is a powerful method to detect ALK-positive non-small cell lung carcinomas.
    Wagner F; Streubel A; Roth A; Stephan-Falkenau S; Mairinger T
    J Clin Pathol; 2014 May; 67(5):403-7. PubMed ID: 24293609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
    J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
    Singh A; Kumar R; Shetty O; Desai S; Rane S
    Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 28. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
    Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
    BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms.
    Mayer C; Ofek E; Fridrich DE; Molchanov Y; Yacobi R; Gazy I; Hayun I; Zalach J; Paz-Yaacov N; Barshack I
    Mod Pathol; 2022 Dec; 35(12):1882-1887. PubMed ID: 36057739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALK and ROS1 rearrangement tested by ARMS-PCR in non-small-cell lung cancer patients via cytology specimens: The experience of Shanghai Pulmonary Hospital.
    Cao Z; Wu W; Zhang W; Li Z; Gao C; Huang Y; Zhang L
    Diagn Cytopathol; 2020 Jun; 48(6):524-530. PubMed ID: 32150350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.
    Schildhaus HU; Deml KF; Schmitz K; Meiboom M; Binot E; Hauke S; Merkelbach-Bruse S; Büttner R
    Mod Pathol; 2013 Nov; 26(11):1468-77. PubMed ID: 23743932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
    Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
    Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.